NLM Digital Collections

Search

Start Over Subjects Drug Industry -- economics ✖Remove constraint Subjects: Drug Industry -- economics

1. Potential misclassifications reported by drug manufacturers may have led to $1 billion in lost Medicaid rebates

Publication:
[Washington, D.C.] : U.S. Department of Health and Human Services, Office of Inspector General, December 2017
Subject(s):
Drug Costs
Drug Industry -- economics
Medicaid -- economics
Pharmaceutical Preparations -- classification
Pharmaceutical Preparations -- economics
Insurance, Health, Reimbursement
Insurance, Pharmaceutical Services
Humans
United States
United States. Department of Health and Human Services.
Centers for Medicare & Medicaid Services (U.S.)

3. Getting to the root of high prescription drug prices: drivers and potential solutions

Author(s):
Waxman, Henry, author
Corr, Bill, author
Martin, Kristi, author
Duong, Sophia, author
Publication:
[New York, N.Y.] : Commonwealth Fund, July 2017
Subject(s):
Cost Control
Drug Costs
Health Policy
Prescription Drugs -- economics
Drug Industry -- economics
Drugs, Generic -- economics
Economic Competition
Legislation, Drug
Orphan Drug Production -- economics
Humans
United States

8. Drug industry: profits, research and development spending, and merger and acquisition deals : report to Congressional requesters

Publication:
Washington, DC : United States Government Accountability Office, November 2017
Subject(s):
Drug Costs
Drug Industry -- economics
Economics, Pharmaceutical -- trends
Pharmaceutical Research -- economics
Pharmaceutical Research -- trends
Antitrust Laws
Biological Products -- economics
Drug Approval -- economics
Drug Development -- economics
Drug Development -- trends
Economic Competition
Forecasting
Orphan Drug Production -- economics
Taxes
Humans
United States
National Institutes of Health (U.S.)